125 related articles for article (PubMed ID: 34084482)
21. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
Meyerhardt JA; Heseltine D; Ogino S; Clark JW; Enzinger PC; Ryan DP; Earle CC; Zhu AX; Fuchs CS
Clin Colorectal Cancer; 2006 May; 6(1):59-65. PubMed ID: 16796793
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study.
Montaudié H; Viotti J; Combemale P; Dutriaux C; Dupin N; Robert C; Mortier L; Kaphan R; Duval-Modeste AB; Dalle S; De Quatrebarbes J; Stefan A; Brunet-Possenti F; Kogay M; Picard-Gauci A; Poissonnet G; Peyrade F
Oncotarget; 2020 Jan; 11(4):378-385. PubMed ID: 32064041
[TBL] [Abstract][Full Text] [Related]
25. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
Bauman JE; Eaton KD; Martins RG
Arch Dermatol; 2007 Jul; 143(7):889-92. PubMed ID: 17638733
[TBL] [Abstract][Full Text] [Related]
26. [Long-term beneficial effects of cetuximab in a woman with metastasised rectal carcinoma without expression of the epidermal growth factor receptor].
Kroep JR; Gelderblom H; Collen AF; Nortier JW
Ned Tijdschr Geneeskd; 2006 Nov; 150(46):2555-9. PubMed ID: 17152334
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.
Hoffmann S; Burchert A; Wunderlich A; Wang Y; Lingelbach S; Hofbauer LC; Rothmund M; Zielke A
Endocrine; 2007 Apr; 31(2):105-13. PubMed ID: 17873319
[TBL] [Abstract][Full Text] [Related]
28. [Establishment of animal models of epidermal growth factor receptor inhibitor-related rashes].
Zhang X; Xue C; Li J; Zhang J; Tan K; Jiang X; Zheng H; Dong H; Yu Y; Hu Z; Cui H
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Mar; 41(3):352-357. PubMed ID: 33849825
[TBL] [Abstract][Full Text] [Related]
29. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
30. Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy.
Lattanzio L; Denaro N; Vivenza D; Varamo C; Strola G; Fortunato M; Chamorey E; Comino A; Monteverde M; Lo Nigro C; Milano G; Merlano M
Cancer Immunol Immunother; 2017 May; 66(5):573-579. PubMed ID: 28197666
[TBL] [Abstract][Full Text] [Related]
31. Treatment of advanced head and neck cancer with cetuximab.
Merlano M; Garrone O
Int J Biol Markers; 2007; 22(1 Suppl 4):S71-6. PubMed ID: 17520584
[TBL] [Abstract][Full Text] [Related]
32. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
33. Thrombotic microangiopathy associated with cetuximab, an epidermal growth factor receptor inhibitor
.
Koizumi M; Takahashi M; Murata M; Kikuchi Y; Seta K; Yahata K
Clin Nephrol; 2017 Jan; 87 (2017)(1):51-54. PubMed ID: 27925578
[TBL] [Abstract][Full Text] [Related]
34. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis.
Joerger M; Matter-Walstra K; Früh M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
Ann Oncol; 2011 Mar; 22(3):567-574. PubMed ID: 20843984
[TBL] [Abstract][Full Text] [Related]
35. A potential link between desmoglein 3 and epidermal growth factor receptor in oral squamous cell carcinoma and its effect on cetuximab treatment efficacy.
Minabe M; Akiyama Y; Higa K; Tachikawa T; Takahashi S; Nomura T; Kouno M
Exp Dermatol; 2019 May; 28(5):614-617. PubMed ID: 30907457
[TBL] [Abstract][Full Text] [Related]
36. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity.
Carcereny E; Maurel J
Rev Recent Clin Trials; 2006 May; 1(2):113-8. PubMed ID: 18473962
[TBL] [Abstract][Full Text] [Related]
38. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study.
Hughes S; Liong J; Miah A; Ahmad S; Leslie M; Harper P; Prendiville J; Shamash J; Subramaniam R; Gaya A; Spicer J; Landau D
J Thorac Oncol; 2008 Jun; 3(6):648-51. PubMed ID: 18520806
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of Cetuximab in Combination with Chemotherapy in Advanced Non-small Cell Lung Cancer].
Yang S; Wang Y; Hu X; Wang H; Hao X; Xu J; Wang L; Wang B; Li J; Zhao L; Jiang P; Qu F; Zhang X; Shi Y
Zhongguo Fei Ai Za Zhi; 2016 May; 19(5):263-8. PubMed ID: 27215454
[TBL] [Abstract][Full Text] [Related]
40. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
